- Home
- RPID vs PLX Comparison
RPID vs PLX Comparison
Compare RPID & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPID
- PLX
- Stock Information
- Founded
- RPID 2006
- PLX 1993
- Country
- RPID United States
- PLX United States
- Employees
- RPID N/A
- PLX N/A
- Industry
- RPID Medical Specialities
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPID Health Care
- PLX Health Care
- Exchange
- RPID Nasdaq
- PLX Nasdaq
- Market Cap
- RPID 145.1M
- PLX 160.2M
- IPO Year
- RPID 2021
- PLX 1998
- Fundamental
- Price
- RPID $3.33
- PLX $1.55
- Analyst Decision
- RPID Buy
- PLX Strong Buy
- Analyst Count
- RPID 1
- PLX 1
- Target Price
- RPID $8.00
- PLX $15.00
- AVG Volume (30 Days)
- RPID 163.7K
- PLX 1.4M
- Earning Date
- RPID 05-09-2025
- PLX 05-09-2025
- Dividend Yield
- RPID N/A
- PLX N/A
- EPS Growth
- RPID N/A
- PLX N/A
- EPS
- RPID N/A
- PLX 0.05
- Revenue
- RPID $29,645,000.00
- PLX $59,764,000.00
- Revenue This Year
- RPID $18.54
- PLX $65.02
- Revenue Next Year
- RPID $20.55
- PLX $57.34
- P/E Ratio
- RPID N/A
- PLX $32.18
- Revenue Growth
- RPID 28.36
- PLX 0.18
- 52 Week Low
- RPID $0.58
- PLX $0.82
- 52 Week High
- RPID $4.04
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- RPID 61.61
- PLX 30.03
- Support Level
- RPID $3.15
- PLX $1.54
- Resistance Level
- RPID $3.84
- PLX $1.79
- Average True Range (ATR)
- RPID 0.27
- PLX 0.11
- MACD
- RPID 0.02
- PLX -0.02
- Stochastic Oscillator
- RPID 50.96
- PLX 27.27
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.